An important gap in the understanding of the pathophysiological role of glucagon in metabolic diseases lies in elucidating whether increased plasma levels of glucagon result from: (1) obesity, (2) MASLD, (3) type 2 diabetes, or (4) a combination of these. The gene discussed is GCG; the disease is type 2 diabetes mellitus.